Beeline's Oral Lupus Drug, Spun Out of Bristol Myers, Beats Placebo at All Three Doses
- Beeline's Phase 2 trial of afimetoran, an oral TLR7/8 inhibitor licensed from Bristol Myers Squibb, met its primary endpoint in systemic lupus erythematosus.
- All three doses beat placebo on the SRI-4 response rate at week 48 in a dose-ranging study of adults on background therapy.
- No new safety signals were reported; Beeline plans pivotal trials in SLE and cutaneous lupus, with full data at a coming congress.
💡 Points Based on public reports
A clean win at every dose is what Beeline needed to justify taking a drug BMS chose to shelve, and it validates the spin-out model for pipeline assets big pharma deprioritizes. The topline gave no effect sizes, though, and an SRI-4 gap over placebo has to be weighed against the other oral lupus entrants. Watch the dose-response shape and infection rates before pricing in a pivotal-trial success.
📰 Source · Fierce Biotech ↗ Beeline flies into phase 3 as oral lupus drug soars past placebo